CL2017000844A1 - Proceso mejorado para la conjugación y conjugados sintéticos de oligosacarido-proteina novedosos obtenidos del mismo. - Google Patents

Proceso mejorado para la conjugación y conjugados sintéticos de oligosacarido-proteina novedosos obtenidos del mismo.

Info

Publication number
CL2017000844A1
CL2017000844A1 CL2017000844A CL2017000844A CL2017000844A1 CL 2017000844 A1 CL2017000844 A1 CL 2017000844A1 CL 2017000844 A CL2017000844 A CL 2017000844A CL 2017000844 A CL2017000844 A CL 2017000844A CL 2017000844 A1 CL2017000844 A1 CL 2017000844A1
Authority
CL
Chile
Prior art keywords
synthetic
conjugation
oligosacárido
conjugates
batterial
Prior art date
Application number
CL2017000844A
Other languages
English (en)
Inventor
Davinder Gill
Manoj Kumar Chhikara
Rakesh Rana
Juned Dalal
Deepti Singh
Original Assignee
Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Wellcome Trust Hilleman Laboratories Pvt Ltd filed Critical Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Publication of CL2017000844A1 publication Critical patent/CL2017000844A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>PROCESO MEJORADO DE CONJUGACIÓN PARA OBTENER NUEVOS CONJUGADOS SINTÉTICOS DE OLIGOSACÁRIDOS SINTÉTICOS- PROTEÍNAS (OS-PR). EL MÉTODO DE CONJUGACIÓN OS-PR SINTÉTICO ES UN MÉTODO RÁPIDO PARA LA OBTENCIÓN DE CONJUGADOS DE OLIGOSACÁRIDO-PROTEÍNA QUE SON ALTAMENTE INMUNOGÉNICOS Y PROVOCAN RESPUESTAS INMUNITARIAS ESPECÍFICAS Y HOMOGÉNEAS. EL OLIGOSACÁRIDO SINTÉTICO COMPRENDE DE CUATRO A OCHO UNIDADES DE REPETICIÓN QUE CONSISTEN EN SUS RESPECTIVOS MONÓMEROS Y AL MENOS UN ENLAZADOR AMINO-TERMINAL INTEGRADO, DICHO POLISACÁRIDO SINTÉTICO QUE IMITA UN POLISACÁRIDO NATURAL OBTENIDO A PARTIR DE BACTERIAS GRAM NEGATIVAS TALES COMO NEISSERIA  MENINGITIDIS SEROGRUPOS, A, C, Y W, X Y HAEMOPHILUS INFLUENZAE Y LA PROTEÍNA PORTADORA, SE OBTIENE A PARTIR DE BACTERIAS GRAM-POSITIVAS TALES COMO CLOSTRIDIUM TETANI (TOXOIDE TETÁNICO) O CORYNEBACLTERIUM DIPHTHERIAE (CRM197) O SUS VERSIONES RECOMBINANTE. LA CONJUGACIÓN QUÍMICA DE DICHO OLIGOSACÁRIDO-PROTEÍNA CONJUGADO, DE ACUERDO CON LA INVENCIÓN, ES EL ENLACE TIO-ÉTER. LA PRESENTE INVENCIÓN TIENE UN TIEMPO PARA COMPLETAR EL PROCESO EN EL INTERVALO DE 14 A <em>22 </em>HORAS. DICHOS CONJUGADOS DE OLIGOSACÁRIDOPROTEÍNA SON ÚTILES EN LA PRODUCCIÓN DE VACUNAS MONOVALENTES O POLIVALENTES Y COMO HERRAMIENTAS DE DIAGNÓSTICO.</p>
CL2017000844A 2014-10-09 2017-04-06 Proceso mejorado para la conjugación y conjugados sintéticos de oligosacarido-proteina novedosos obtenidos del mismo. CL2017000844A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2884DE2014 2014-10-09

Publications (1)

Publication Number Publication Date
CL2017000844A1 true CL2017000844A1 (es) 2017-12-22

Family

ID=55652678

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000844A CL2017000844A1 (es) 2014-10-09 2017-04-06 Proceso mejorado para la conjugación y conjugados sintéticos de oligosacarido-proteina novedosos obtenidos del mismo.

Country Status (18)

Country Link
US (1) US10105438B2 (es)
EP (1) EP3204396A4 (es)
JP (1) JP2017531662A (es)
KR (1) KR20170065030A (es)
CN (1) CN106795194A (es)
AU (1) AU2015329590B2 (es)
BR (1) BR112017006447A2 (es)
CA (1) CA2963900A1 (es)
CL (1) CL2017000844A1 (es)
CO (1) CO2017003291A2 (es)
CU (1) CU20170046A7 (es)
EA (1) EA201700177A1 (es)
IL (1) IL251511A0 (es)
MX (1) MX2017004495A (es)
PH (1) PH12017500579A1 (es)
SG (1) SG11201702451WA (es)
TN (1) TN2017000126A1 (es)
WO (1) WO2016055957A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170198004A1 (en) 2014-05-24 2017-07-13 Biological E Limited Novel semi-synthetic meningococcal conjugate vaccine
CN107709341A (zh) * 2015-07-28 2018-02-16 Msd韦尔科姆信托希尔曼实验室私人有限公司 新的脑膜炎奈瑟氏菌血清组y寡聚体及其合成方法
SI3506935T1 (sl) * 2016-09-02 2024-06-28 Sanofi Pasteur, Inc. Cepivo proti neisseriji meningitidis
US10688170B2 (en) 2017-06-10 2020-06-23 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
BR112020018974A2 (pt) * 2018-03-23 2021-01-05 Koranex Capital Glicoconjugados de precisão como ferramentas terapêuticas
JP2023537945A (ja) 2020-08-10 2023-09-06 インベントプライズ・インコーポレイテッド 出現血清型２４ｆを含む多価肺炎球菌複合糖質ワクチン
CN113274488B (zh) * 2021-04-30 2023-08-29 山东省药学科学院 一种特异性预防真菌感染的寡糖疫苗及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434668A1 (en) * 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
EP1885734B1 (en) * 2005-05-06 2015-01-14 Novartis AG Immunogens for meningitidis-a vaccines
FR2904627B1 (fr) * 2006-08-04 2008-11-07 Pasteur Institut Nouveaux peptides actives, purifies et isoles, derives du recepteur cd4 (mini-cd4) et leur procece de preparation
EP2648506A1 (en) * 2010-12-10 2013-10-16 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process

Also Published As

Publication number Publication date
MX2017004495A (es) 2017-12-18
WO2016055957A1 (en) 2016-04-14
EP3204396A4 (en) 2018-03-28
PH12017500579A1 (en) 2017-08-30
AU2015329590B2 (en) 2019-08-22
CA2963900A1 (en) 2016-04-14
US10105438B2 (en) 2018-10-23
TN2017000126A1 (en) 2018-10-19
BR112017006447A2 (pt) 2017-12-12
CN106795194A (zh) 2017-05-31
SG11201702451WA (en) 2017-04-27
KR20170065030A (ko) 2017-06-12
AU2015329590A1 (en) 2017-05-04
EP3204396A1 (en) 2017-08-16
CU20170046A7 (es) 2017-06-05
EA201700177A1 (ru) 2017-07-31
IL251511A0 (en) 2017-05-29
CO2017003291A2 (es) 2017-06-30
JP2017531662A (ja) 2017-10-26
US20170246313A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
CL2017000844A1 (es) Proceso mejorado para la conjugación y conjugados sintéticos de oligosacarido-proteina novedosos obtenidos del mismo.
MX2013013111A (es) Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma.
MX2021000193A (es) Selección de epítopos de vacunas personalizadas contra el cáncer.
BR112017014258A2 (pt) anticorpos anti-cd47 e usos dos mesmos
BR102014027436A8 (pt) Sequência recombinante, uso de uma planta, uma parte de planta, ou uma célula de planta de soja, método para preparação de uma célula de planta transgênica, e sequências genômica recombinante e purificada de soja
MY183507A (en) Process for rearing insects
BR112015006393A2 (pt) método para produzir um produto de tecido, produto de tecido produzido por um processo, e método de tratamento
BR112013030492A2 (pt) método para produzir um produto de tecido, produto de tecido produzido por um processo, método de tratamento, e sistema de tratamento
CO2020001927A2 (es) Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3
MX366206B (es) Vacuna de antígeno micobacteriano.
BR112017010793A2 (pt) animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
MX360823B (es) Vacunas individualizadas para el cancer.
PH12020550660A1 (en) Cultivation of placenta to isolate exosomes
CO2017002804A2 (es) Anticuerpo anti-repeticiones de dipeptido (dpr) derivado de humano
MY172601A (en) Improved process for preparing fermented soybean meal
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
PH12015501101A1 (en) Method for eliciting an immune response to an immunogen
BR112016013845A2 (pt) Métodos de perfilagem de epítopos de células t, produção de composições de células t e tratamento de doenças
MX2018010920A (es) Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos.
BR112012030659B8 (pt) Parvovírus vivo atenuado, vacinas que o compreendem e método para a fabricação das referidas vacinas
CR20140559A (es) Metodo para producir antígenos de haemophilus influenzae de tipo b
AR103531A1 (es) Composiciones de caldo y su uso como prebióticos
MX2015008944A (es) Proceso de liofilizacion.
BR112017000391A2 (pt) métodos para a produção de um material lignocelulósico, de um açúcar fermentável e de um produto de fermentação, material lignocelulósico parcialmente hidrolisado, açúcar fermentável, produto de fermentação e aparelho para a produção de um material lignocelulósico
BR112012026705A2 (pt) método para produzir um produto natural fermentado.